IGI Logo

Astrazeneca Pharma India is currently trading at Rs. 3160.40, up by 49.90 points or 1.60% from its previous closing of Rs. 3110.50 on the BSE.

The scrip opened at Rs. 3092.00 and has touched a high and low of Rs. 3179.00 and Rs. 3092.00 respectively. So far 781 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3350.00 on 29-Nov-2021 and a 52 week low of Rs. 2437.75 on 12-May-2022.

Last one week high and low of the scrip stood at Rs. 3179.00 and Rs. 3012.10 respectively. The current market cap of the company is Rs. 7776.25 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 3.78% and 21.22% respectively.

AstraZeneca Pharma India has received Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India (DCGI) for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.

Through this approval, Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.The receipt of this permission paves way for the launch of Olaparib Film-Coated Tablets 100 mg and 150 mg (Lynparza) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.